Overview

• Plasma-activated medium (PAM), developed using non-thermal atmospheric-pressure plasma, reduced synovial sarcoma cell viability to 21% in vitro.
• In mouse models, daily PAM injections over four weeks reduced tumor volume by 54% and tumor weight by 41% without observable side effects.
• The treatment selectively induces oxidative stress and apoptosis in cancer cells through reactive oxygen and nitrogen species, sparing healthy cells.
• The study highlights PAM's potential as a safer, low-toxicity alternative to conventional therapies for aggressive cancers like synovial sarcoma.
• Published in the journal *Biomedicines*, the findings pave the way for further optimization and eventual clinical trials to assess efficacy in humans.